Last reviewed · How we verify
NCT03474536: AFFIHLA-P
Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation
trial in Lung Transplantation in 88 participants. Completed in 8 April 2025.
8 April 2025
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 14 March 2018 |
| Primary completion | 8 April 2025 |
| Estimated completion | 8 April 2025 |
| Sites | 5 locations across France |
Conditions studied
- Lung Transplantation — all drugs for Lung Transplantation →
- Antibody Mediated Rejection — all drugs for Antibody Mediated Rejection →
- Chronic Lung Allograft Dysfunction — all drugs for Chronic Lung Allograft Dysfunction →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Lung Transplantation or Antibody Mediated Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim is to compare the quantitative parameters of de novo anti-HLA DQ Donor Specific Antibodies (DSA), determined at the time of their discovery by surface plasmon resonance (SPR), between recipients that developed a Chronic Lung Allograft Dysfunction (CLAD) for the 2 years following DSA apparition and those who did not. If concentration, kinetics and/or affinity parameters of anti-DQ DSA are associated with CLAD development, new, non-invasive prognostic biomarkers of humoral rejection in lung transplantation will be discovered .
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03474536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Transplantation
Currently open trials in the same condition.
- NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
- NCT06853223 — This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction · Phase 2 · recruiting
- NCT06868823 — Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation · recruiting
- NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
- NCT06327945 — Transplanting Lungs From Uncontrolled Donation After Circulatory Death · NA · recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03474536 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03474536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing